Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 120

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 120
---
 subject to refunds, and, under certain circumstances, we may be required to notify applicable regulatory authorities about such refunds. If our products are subject to refunds or delivery holds, our reputation, business, financial condition, or results of operations could be adversely affected. We rely on a limited number of suppliers or, in some cases, sole suppliers for raw materials, key components or laboratory instruments, and an interruption in our ability to obtain such materials and services could adversely affect our business. We do not have manufacturing capabilities and do not plan to develop such capacity in the foreseeable future. Accordingly, we rely on a limited number of suppliers, or, in some cases, sole suppliers, including Illumina, Amoy Diagnostics Co., Ltd., Sophia Genetics SA and CIBIC, for reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations, and GNX Data Systems Ltd platform for genomic variant analysis. Pursuant to the Commercialization Agreement, we have established arrangements with CIBIC for the supply of reagents and equipment required for our operations. Further, as CIBIC sources reagents from Illumina, we also have the option to purchase the reagents directly from Illumina, if required. Additionally, we plan to develop strategic partnerships with other laboratories and players in the healthcare sector that share similar supply chain risks. These partnerships could amplify the effects of any supply chain issues. Currently, we do not have short- or long -termsupply agreements for our Argentine Wet Lab, and these suppliers could cease supplying these materials and equipment at any time or fail to provide us with sufficient quantities of materials or materials that meet our specifications. Our laboratory operations in Argentina, as well as those of our partner laboratories, could be interrupted if we encounter delays or difficulties in securing these reagents, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. As an alternative to CIBIC, we may rely on Illumina for the supply of next generation sequencers, associated reagents and maintenance and repair services for these sequencers. Any disruption in Illumina’s operations could affect our supply chain and laboratory operations in the short term, as Illumina is also a supplier to CIBIC. Additionally, transitioning to alternative providers could require a substantial amount of time to integrate replacement equipment and reagents into our laboratory operations potentially affecting our ability to provide our services during the transition period. We believe that there are only a few